Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Arthrosurface, a leading provider of joint restoration and preservation solutions, has been acquired from Anika Therapeutics (NASDAQ: ANIK) by Primo Medical Group executives and former Arthrosurface leaders. The company specializes in minimally invasive techniques with a portfolio of over 150 different surface implant curvatures for knee, shoulder, wrist, and toe treatments. Under new ownership through Phoenix Brio, Arthrosurface will maintain its operations in West Bridgewater, Massachusetts, with no expected disruption to product access or customer service.
Arthrosurface, un fornitore leader di soluzioni per il ripristino e la preservazione delle articolazioni, è stata acquisita dai dirigenti di Primo Medical Group e dagli ex leader di Arthrosurface da Anika Therapeutics (NASDAQ: ANIK). L'azienda si specializza in tecniche minimamente invasive con un portafoglio di oltre 150 diverse curvature di impianto superficiale per trattamenti di ginocchio, spalla, polso e dita dei piedi. Sotto la nuova proprietà tramite Phoenix Brio, Arthrosurface manterrà le proprie operazioni a West Bridgewater, nel Massachusetts, senza aspettarsi interruzioni nell'accesso ai prodotti o nel servizio clienti.
Arthrosurface, un proveedor líder de soluciones de restauración y preservación de articulaciones, ha sido adquirida de Anika Therapeutics (NASDAQ: ANIK) por ejecutivos de Primo Medical Group y antiguos líderes de Arthrosurface. La empresa se especializa en técnicas mínimamente invasivas con un portafolio de más de 150 diferentes curvaturas de implantes superficiales para tratamientos de rodilla, hombro, muñeca y dedos del pie. Bajo la nueva propiedad a través de Phoenix Brio, Arthrosurface mantendrá sus operaciones en West Bridgewater, Massachusetts, sin interrupciones esperadas en el acceso a los productos o al servicio al cliente.
관절 복원 및 보존 솔루션의 선도적인 제공업체인 Arthrosurface는 Anika Therapeutics (NASDAQ: ANIK)에서 Primo Medical Group의 임원들과 이전 Arthrosurface 리더들에 의해 인수되었습니다. 이 회사는 무릎, 어깨, 손목 및 발가락 치료를 위한 150가지 이상의 다양한 표면 임플란트 곡률로 구성된 포트폴리오를 가진 최소 침습 기술을 전문으로 합니다. Phoenix Brio를 통해 새로운 소유권 하에 Arthrosurface는 매사추세츠주 웨스트 브리지워터에서 운영을 계속하며, 제품 접근성이나 고객 서비스에 대한 중단이 없을 것으로 예상됩니다.
Arthrosurface, un fournisseur leader de solutions de restauration et de préservation des articulations, a été acquis de Anika Therapeutics (NASDAQ: ANIK) par des dirigeants de Primo Medical Group et d'anciens responsables d'Arthrosurface. L'entreprise se spécialise dans des techniques peu invasives avec un portefeuille de plus de 150 courbures d'implants de surface différents pour les traitements du genou, de l'épaule, du poignet et des orteils. Sous une nouvelle propriété par l'intermédiaire de Phoenix Brio, Arthrosurface maintiendra ses opérations à West Bridgewater, dans le Massachusetts, sans interruption prévue de l'accès aux produits ou du service client.
Arthrosurface, ein führender Anbieter von Lösungen zur Gelenkerhaltung und -wiederherstellung, wurde von den Führungskräften der Primo Medical Group und ehemaligen Führungskräften von Arthrosurface von Anika Therapeutics (NASDAQ: ANIK) übernommen. Das Unternehmen spezialisiert sich auf minimalinvasive Techniken mit einem Portfolio von über 150 verschiedenen Oberflächenimplantat-Krümmungen für Behandlungen des Knies, der Schulter, des Handgelenks und der Zehen. Unter neuer Eigentümerschaft durch Phoenix Brio wird Arthrosurface seine Operationen in West Bridgewater, Massachusetts, beibehalten, ohne dass mit Unterbrechungen beim Produktzugang oder Kundenservice zu rechnen ist.
- Portfolio includes over 150 different surface implant curvatures for multiple joint treatments
- Business continuity assured with no disruption to product access or customer service
- Experienced leadership team including former Arthrosurface executives
- Divestiture from Anika Therapeutics indicates strategic shift/restructuring
Insights
This divestiture marks a significant shift in Anika Therapeutics' business strategy. The sale of Arthrosurface, which was originally acquired by Anika in 2020 for
The move suggests Anika is streamlining its portfolio, potentially to focus on core assets and improve operational efficiency. For investors, this raises questions about Anika's growth strategy and future revenue projections. The company's joint preservation segment has been a significant revenue contributor and this divestiture could lead to short-term revenue headwinds.
The return of Arthrosurface to its original leadership team, backed by Primo Medical Group, could reinvigorate the brand's market presence. With a portfolio of over 150 surface implant curvatures and established clinical history, Arthrosurface maintains strong positioning in the joint preservation market. The continuation of product availability and service levels should maintain market stability.
The joint preservation market continues to grow, driven by increasing demand for minimally invasive procedures and an aging, active population. This transaction reflects ongoing consolidation trends in the medical device sector, where specialized players often perform better independently than within larger corporate structures.
Arthrosurface: A Pioneer in Joint Restoration and Preservation
Shane Shankle, who was appointed Arthrosurface's new President said, "As a leader in joint preservation, I'm excited to drive our company's growth plan by delivering products that help patients maintain an active quality of life." Frank Fedorowicz, Chief Operating and Financial Officer, added, "I'm very happy to be reunited with many of our founding executives to propel Arthrosurface into its next exciting phase."
With a commitment to minimally invasive techniques, Arthrosurface products are designed to restore natural joint function while preserving surrounding bone and tissue. Arthrosurface's product portfolio includes more than 150 different surface implant curvatures for the knee, shoulder, wrist and toe that are designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Andrea Patisteas, Senior Executive Vice President emphasized that "With over two decades of clinical experience with our implants, we're thrilled to continue working with physicians and patients to provide them with options for the treatment of orthopedic conditions." Steven Tallarida, President and CEO of Primo Medical Group simply commented "It is great to be back!"
Phoenix Brio will be Arthrosurface's parent company, and both will be based in
Customers and distributors of Arthrosurface products should not expect to see any change in service or disruption in product access or availability.
About Primo Medical Group
Primo Medical Group offers the most comprehensive outsourcing solutions for the medical device market, including OEM product distribution services, engineering services, precision component production, finished goods assembly, medical device refurbishment, reusable surgical kit management and complete supply chain management. Established in 1953, Primo Medical Group is a privately held company with five facilities in Massachusetts. Primo Medical Group is an FDA Registered Contract Manufacturer and is compliant with FDA Quality Systems Regulations. Primo Medical Group is also ISO 13485:2016 certified and is a registered manufacturer with the Office of Defense Trade Controls Compliance. Over the past 24 years Primo Medical Group has incubated and co-funded several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface (acquired by Anika Therapeutics), Spirus Medical, Inc. (acquired by Olympus), Saphena Medical Inc. (acquired by a major strategic in 2024), Cardiosolutions, Inc., Trax Surgical, Inc. and Versago Vascular Access.
For media inquiries, please contact:
Andrea Patisteas
781-828-4400
andreap@primomedicalgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/arthrosurface-returns-to-it-roots-following-divestiture-from-anika-therapeutics-302292970.html
SOURCE Primo Medical Group
FAQ
What happened to Arthrosurface's ownership from Anika Therapeutics (ANIK)?
How many different surface implant products does Arthrosurface offer?
Will there be any changes to Arthrosurface's product availability after the acquisition from ANIK?
